Keyphrases
Cost-effectiveness
100%
Locally Advanced Rectal Cancer
100%
Total Neoadjuvant Therapy
100%
Short-course Radiotherapy
100%
Quality-adjusted Life Years
88%
Long-course Chemoradiotherapy
77%
Transanal Total Mesorectal Excision (taTME)
55%
Adjuvant Chemotherapy
33%
Treatment Strategy
22%
Sensitivity Analysis
22%
Rectal Adenocarcinoma
22%
Treatment Paradigms
22%
Incremental Cost-effectiveness Ratio
22%
Locally Advanced
22%
Net Monetary Benefit
22%
Disease Progression
11%
Newly Diagnosed
11%
Medicare
11%
In(III)
11%
Patient Survival
11%
Biopsy-proven
11%
Cost-effectiveness Analysis
11%
Decision-analytic Model
11%
Cost Savings
11%
Economic Implications
11%
Willingness-to-pay Threshold
11%
Willingness to Pay
11%
Payer Perspective
11%
Markov Modeling
11%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Neoadjuvant Therapy
100%
Rectum Cancer
100%
Radiation Therapy
100%
Quality Adjusted Life Year
88%
Chemoradiotherapy
77%
Health Care Cost
66%
Total Mesorectal Excision
55%
Adjuvant Chemotherapy
33%
Rectum Carcinoma
22%
Disease Exacerbation
11%
Medicare
11%
Biopsy Technique
11%
Pharmacology, Toxicology and Pharmaceutical Science
Chemoradiation Therapy
100%
Rectum Cancer
100%
Chemotherapy
42%
Rectum Carcinoma
28%
Disease Exacerbation
14%